Burchard GD, et al. Plasmodium falciparum-malaria: resistance to chloroquine, but sensitivity to mefloquine in the Gabon. A prospective in-vitro study. Tropenmed Parasitol. 1984;35(1):1–4.
Kremsner PG, et al. Curing of chloroquine-resistant malaria with clindamycin. Am J Trop Med Hyg. 1993;49(5):650–4.
Kremsner PG, et al. Clindamycin in combination with chloroquine or quinine is an effective therapy for uncomplicated Plasmodium falciparum malaria in children from Gabon. J Infect Dis. 1994;169(2):467–70.
Kremsner PG, et al. Comparison of micronized halofantrine with chloroquine-antibiotic combinations for treating Plasmodium falciparum malaria in adults from Gabon. Am J Trop Med Hyg. 1994;50(6):790–5.
Metzger W, et al. High efficacy of short-term quinine-antibiotic combinations for treating adult malaria patients in an area in which malaria is hyperendemic. Antimicrob Agents Chemother. 1995;39(1):245–6.
Metzger W, et al. Sulfadoxine/pyrimethamine or chloroquine/clindamycin treatment of Gabonese school children infected with chloroquine resistant malaria. J Antimicrob Chemother. 1995;36(4):723–8.
Kremsner PG, et al. Quinine plus clindamycin improves chemotherapy of severe malaria in children. Antimicrob Agents Chemother. 1995;39(7):1603–5.
Radloff PD, et al. Atovaquone and proguanil for Plasmodium falciparum malaria. Lancet. 1996;347(9014):1511–4.
Kremsner PG, Looareesuwan S, Chulay JD. Atovaquone and proguanil hydrochloride for treatment of malaria. J Travel Med. 1999;6(Suppl 1):S18–20.
Lell B, et al. Randomised placebo-controlled study of atovaquone plus proguanil for malaria prophylaxis in children. Lancet. 1998;351(9104):709–13.
Radloff PD, et al. Arteflene compared with mefloquine for treating Plasmodium falciparum malaria in children. Am J Trop Med Hyg. 1996;55(3):259–62.
Schmidt-Ott R, et al. Pyrimethamine/sulfadoxine for treating uncomplicated Plasmodium falciparum malaria in young children in Gabon. Trans R Soc Trop Med Hyg. 1997;91(5):578–9.
Adjuik M, et al. Amodiaquine-artesunate versus amodiaquine for uncomplicated Plasmodium falciparum malaria in African children: a randomised, multicentre trial. Lancet. 2002;359(9315):1365–72.
Ramharter M, et al. Artesunate-clindamycin versus quinine-clindamycin in the treatment of Plasmodium falciparum malaria: a randomized controlled trial. Clin Infect Dis. 2005;40(12):1777–84.
Ramharter M, et al. Fixed-dose pyronaridine-artesunate combination for treatment of uncomplicated falciparum malaria in pediatric patients in Gabon. J Infect Dis. 2008;198(6):911–9.
Borrmann S, et al. Short-course regimens of artesunate-fosmidomycin in treatment of uncomplicated Plasmodium falciparum malaria. Antimicrob Agents Chemother. 2005;49(9):3749–54.
The Four Artemisinin-Based Combinations (4ABC) Study Group. A head-to-head comparison of four artemisinin-based combinations for treating uncomplicated malaria in African children: a randomized trial. PLoS Med. 2011;8(11):e1001119.
Lell B, et al. Malaria chemoprophylaxis with tafenoquine: a randomised study. Lancet. 2000;355(9220):2041–5.
Han Z, Liang SY, Marschall J. Current strategies for the prevention and management of central line-associated bloodstream infections. Infect Drug Resist. 2010;3:147–63.
Missinou MA, et al. Fosmidomycin for malaria. Lancet. 2002;360(9349):1941–2.
Lell B, et al. Fosmidomycin, a novel chemotherapeutic agent for malaria. Antimicrob Agents Chemother. 2003;47(2):735–8.
Wiesner J, Borrmann S, Jomaa H. Fosmidomycin for the treatment of malaria. Parasitol Res. 2003;90(Suppl 2):S71–S6.
Borrmann S, et al. Fosmidomycin-clindamycin for Plasmodium falciparum Infections in African children. J Infect Dis. 2004;189(5):901–8.
Borrmann S, et al. Fosmidomycin-clindamycin for the treatment of Plasmodium falciparum malaria. J Infect Dis. 2004;190(9):1534–40.
Borrmann S, et al. Short report: evaluation of a simple and inexpensive photometric device for the measurement of hemoglobin. Am J Trop Med Hyg. 2004;71(5):691–2.
Borrmann S, et al. Fosmidomycin plus clindamycin for treatment of pediatric patients aged 1 to 14 years with Plasmodium falciparum malaria. Antimicrob Agents Chemother. 2006;50(8):2713–8.
Oyakhirome S, et al. Randomized controlled trial of fosmidomycin-clindamycin versus sulfadoxine-pyrimethamine in the treatment of Plasmodium falciparum malaria. Antimicrob Agents Chemother. 2007;51(5):1869–71.
Mombo-Ngoma G, et al. Efficacy and safety of fosmidomycin-piperaquine as nonartemisinin-based combination therapy for uncomplicated falciparum malaria: a single-arm, age de-escalation proof-of-concept study in Gabon. Clin Infect Dis. 2018;66(12):1823–30.
Alloueche A, et al. Comparison of chlorproguanil-dapsone with sulfadoxine-pyrimethamine for the treatment of uncomplicated falciparum malaria in young African children: double-blind randomised controlled trial. Lancet. 2004;363(9424):1843–8.
Held J, et al. Ferroquine and artesunate in African adults and children with Plasmodium falciparum malaria: a phase 2, multicentre, randomised, double-blind, dose-ranging, non-inferiority study. Lancet Infect Dis. 2015;15(12):1409–19.
Mombo-Ngoma G, et al. Phase I randomized dose-ascending placebo-controlled trials of ferroquine—a candidate anti-malarial drug—in adults with asymptomatic Plasmodium falciparum infection. Malar J. 2011;10:53.
Supan C, et al. Pharmacokinetics of ferroquine, a novel 4‑aminoquinoline, in asymptomatic carriers of Plasmodium falciparum infections. Antimicrob Agents Chemother. 2012;56(6):3165–73.
Macintyre F, et al. A randomised, double-blind clinical phase II trial of the efficacy, safety, tolerability and pharmacokinetics of a single dose combination treatment with artefenomel and piperaquine in adults and children with uncomplicated Plasmodium falciparum malaria. BMC Med. 2017;15(1):181.
Mischlinger J, Agnandji ST, Ramharter M. Single dose treatment of malaria—current status and perspectives. Expert Rev Anti Infect Ther. 2016;14(7):669–78.
Kremsner PG, et al. A simplified intravenous artesunate regimen for severe malaria. J Infect Dis. 2012;205(2):312–9.
Kremsner PG, et al. Intramuscular artesunate for severe malaria in African children: a multicenter randomized controlled trial. PLoS Med. 2016;13(1):e1001938.
Grobusch MP, Kremsner PG. Uncomplicated malaria. Curr Top Microbiol Immunol. 2005;295:83–104.
Adegnika AA, et al. Effectiveness of quinine monotherapy for the treatment of Plasmodium falciparum infection in pregnant women in Lambarene, Gabon. Am J Trop Med Hyg. 2005;73(2):263–6.
Grobusch MP, et al. Intermittent preventive treatment against malaria in infants in Gabon—A randomized, double-blind, placebo-controlled trial. J Infect Dis. 2007;196(11):1595–602.
May J, et al. Therapeutic and prophylactic effect of intermittent preventive anti-malarial treatment in infants (IPTi) from Ghana and Gabon. Malar J. 2008;7:198.
Aponte JJ, et al. Efficacy and safety of intermittent preventive treatment with sulfadoxine-pyrimethamine for malaria in African infants: a pooled analysis of six randomised, placebo-controlled trials. Lancet. 2009;374(9700):1533–42.
González R, et al. Intermittent preventive treatment of malaria in pregnancy with mefloquine in HIV-negative women: a multicentre randomized controlled trial. PLoS Med. 2014;11(9):e1001733.
Ruperez M, et al. Mortality, morbidity, and developmental outcomes in infants born to women who received either mefloquine or sulfadoxine-pyrimethamine as intermittent preventive treatment of malaria in pregnancy: a cohort study. PLoS Med. 2016;13(e1001964):2.
Faucher JF, et al. Efficacy of atovaquone/proguanil for malaria prophylaxis in children and its effect on the immunogenicity of live oral typhoid and cholera vaccines. Clin Infect Dis. 2002;35(10):1147–54.
RTS,S Clinical Trials Partnership. Efficacy and safety of RTS,S/AS01 malaria vaccine with or without a booster dose in infants and children in Africa: final results of a phase 3, individually randomised, controlled trial. Lancet. 2015;386(9988):31–45.
Mordmüller B, et al. Safety and immunogenicity of the malaria vaccine candidate GMZ2 in malaria-exposed, adult individuals from Lambaréné, Gabon. Vaccine. 2010;28(41):6698–703.
Mordmüller B, et al. First-in-human, randomized, double-blind clinical trial of differentially adjuvanted PAMVAC, a vaccine candidate to prevent pregnancy-associated malaria. Clin Infect Dis. 2019;69(9):1509–16.
Dejon-Agobe JC, et al. Controlled human malaria infection of healthy adults with lifelong malaria exposure to assess safety, Immunogenicity, and efficacy of the asexual blood stage malaria vaccine candidate GMZ2. Clin Infect Dis. 2019;69(8):1377–84.
Bélard S, et al. A randomized controlled phase Ib trial of the malaria vaccine candidate GMZ2 in African children. PLoS ONE. 2011;6(7):e22525.
Poetsch JH, et al. Detectable Vesicular Stomatitis virus (VSV)-specific humoral and cellular immune responses following VSV-Ebola virus vaccination in humans. J Infect Dis. 2019;219(4):556–61.
Huttner A, et al. Determinants of antibody persistence across doses and continents after single-dose rVSV-ZEBOV vaccination for Ebola virus disease: an observational cohort study. Lancet Infect Dis. 2018;18(7):738–48.
Agnandji ST, et al. Safety and immunogenicity of rVSV∆G-ZEBOV-GP Ebola vaccine in adults and children in Lambaréné, Gabon: a phase I randomised trial. PLoS Med. 2017;14(10):e1002402.
Rechtien A, et al. Systems vaccinology identifies an early innate immune signature as a correlate of antibody responses to the Ebola vaccine rVSV-ZEBOV. Cell Rep. 2017;20(9):2251–61.
Dahlke C, et al. Dose-dependent T‑cell dynamics and cytokine cascade following rVSV-ZEBOV immunization. EBioMedicine. 2017;19:107–18.
Huttner A, et al. A dose-dependent plasma signature of the safety and immunogenicity of the rVSV-ebola vaccine in Europe and Africa. Sci Transl Med. 2017;9(385):eaaj1701.
Medaglini D, et al. Ebola vaccine R&D: Filling the knowledge gaps. Sci Transl Med. 2015;7(317):317ps24.
Agnandji ST, et al. Phase 1 trials of rVSV ebola vaccine in Africa and Europe. N Engl J Med. 2016;374(17):1647–60.
van Riet E, et al. Cellular and humoral responses to influenza in gabonese children living in rural and semi-urban areas. J Infect Dis. 2007;196(11):1671–8.
van Riet E, et al. Cellular and humoral responses to tetanus vaccination in Gabonese children. Vaccine. 2008;26(29):3690–5.
Esen M, et al. Reduced antibody responses against Plasmodium falciparum vaccine candidate antigens in the presence of Trichuris trichiura. Vaccine. 2012;30(52):7621–4.
Brückner S, et al. Effect of antihelminthic treatment on vaccine immunogenicity to a seasonal influenza vaccine in primary school children in Gabon: a randomized placebo-controlled trial. PLoS Negl Trop Dis. 2015;9(6):e3768.
Brückner S, et al. A single-dose antihelminthic treatment does not influence immunogenicity of a meningococcal and a cholera vaccine in Gabonese school children. Vaccine. 2016;34(44):5384–90.
Planche T, et al. Comparison of methods for the rapid laboratory assessment of children with malaria. Am J Trop Med Hyg. 2001;65(5):599–602.
Taylor T, et al. Standardized data collection for multi-center clinical studies of severe malaria in African children: establishing the SMAC network. Trans R Soc Trop Med Hyg. 2006;100(7):615–22.
Kendjo E, et al. Mortality patterns and site heterogeneity of severe malaria in African children. PLoS ONE. 2013;8(3):e58686.
Kremsner PG, et al. Prognostic value of circulating pigmented cells in African children with malaria. J Infect Dis. 2009;199(1):142–50.
Helbok R, et al. The Lambaréné Organ Dysfunction Score (LODS) is a simple clinical predictor of fatal malaria in African children. J Infect Dis. 2009;200(12):1834–41.
Bélard S, et al. Tuberculosis treatment outcome and drug resistance in Lambaréné, Gabon: a prospective cohort study. Am J Trop Med Hyg. 2016;95(2):472–80.
Alabi AS, et al. Enhanced laboratory capacity development: a boost for effective tuberculosis control in resource-limited settings. Int J Infect Dis. 2017;56:81–4.
Stolp SM, et al. Tuberculosis patients hospitalized in the Albert Schweitzer Hospital, Lambaréné, Gabon—A retrospective observational study. Clin Microbiol Infect. 2013;19(11):E499–E501.
Cremers AL, et al. Perceptions, health care seeking behaviour and implementation of a tuberculosis control programme in Lambaréné, Gabon. Public Health Action. 2013;3(4):328–32.
Janssen S, et al. TB and HIV in the Central African region: current knowledge and knowledge gaps. Infection. 2014;42(2):281–94.
Flamen A, et al. Childhood tuberculosis in Lambaréné, Gabon: tuberculosis control in its infancy? Infection. 2014;42(1):161–4.
Bélard S, et al. Limited access to drugs for resistant tuberculosis: a call to action. J Public Health (Oxf). 2015;37(4):691–3.
Grogan JL, et al. Antischistosome IgG4 and IgE responses are affected differentially by chemotherapy in children versus adults. J Infect Dis. 1996;173(5):1242–7.
Van Etten L, et al. Day-to-day variation of egg output and schistosome circulating antigens in urine of Schistosoma haematobium-infected school children from Gabon and follow-up after chemotherapy. Am J Trop Med Hyg. 1997;57(3):337–41.
van den Biggelaar AH, et al. Decreased atopy in children infected with Schistosoma haematobium: a role for parasite-induced interleukin-10. Lancet. 2000;356(9243):1723–7.
Borrmann S, et al. Artesunate and praziquantel for the treatment of Schistosoma haematobium infections: a double-blind, randomized, placebo-controlled study. J Infect Dis. 2001;184(10):1363–6.
van der Kleij D, et al. Responses to Toll-like receptor ligands in children living in areas where schistosome infections are endemic. J Infect Dis. 2004;189(6):1044–51.
Dejon-Agobe JC, et al. Schistosoma haematobium effects on Plasmodium falciparum infection modified by soil-transmitted helminths in school-age children living in rural areas of Gabon. PLoS Negl Trop Dis. 2018;12(8):e6663.
Mombo-Ngoma G, et al. Urogenital schistosomiasis during pregnancy is associated with low birth weight delivery: analysis of a prospective cohort of pregnant women and their offspring in Gabon. Int J Parasitol. 2017;47(1):69–74.
Mombo-Ngoma G, et al. Loa loa infection in pregnant women, Gabon. Emerg Infect Dis. 2015;21(5):899a–8901.
Adegnika AA, et al. Epidemiology of parasitic co-infections during pregnancy in Lambarene, Gabon. Trop Med Int Health. 2010;15(10):1204–9.
Veletzky L, Hergeth J, Stelzl DR, Mischlinger J, Manego RZ, Mombo-Ngoma G, et al. Burden of disease in Gabon caused by loiasis: a cross-sectional survey. Lancet Infect Dis. 2020;20(11):1339–46.
Adegnika AA, et al. Randomized, controlled, assessor-blind clinical trial to assess the efficacy of single- versus repeated-dose albendazole to treat ascaris lumbricoides, trichuris trichiura, and hookworm infection. Antimicrob Agents Chemother. 2014;58(5):2535–40.
Basra A, et al. Efficacy of mefloquine intermittent preventive treatment in pregnancy against Schistosoma haematobium infection in Gabon: a nested randomized controlled assessor-blinded clinical trial. Clin Infect Dis. 2013;56(6):e68–75.
Roestenberg M, et al. Experimental infection of human volunteers. Lancet Infect Dis. 2018;18(10):e312–e22.
Chen WH, et al. Single-dose live oral cholera vaccine CVD 103-HgR protects against human experimental infection with Vibrio cholerae O1 el Tor. Clin Infect Dis. 2016;62(11):1329–35.
Lell B, et al. Impact of sickle cell trait and naturally acquired immunity on uncomplicated malaria after controlled human malaria infection in adults in Gabon. Am J Trop Med Hyg. 2018;98(2):508–15.
Dejon-Agobe JC, et al. Controlled human malaria infection of healthy lifelong malaria-exposed adults to assess safety, immunogenicity and efficacy of the asexual blood stage malaria vaccine candidate GMZ2. Clin Infect Dis. 2018;69(8):1377–84.
Tong SYC, et al. Novel staphylococcal species that form part of a Staphylococcus aureus-related complex: the non-pigmented Staphylococcus argenteus sp. nov. and the non-human primate-associated Staphylococcus schweitzeri sp. nov. Int J Syst Evol Microbiol. 2015;65(Pt 1):15–22.
Ateba Ngoa U, et al. Epidemiology and population structure of Staphylococcus aureus in various population groups from a rural and semi urban area in Gabon, Central Africa. Acta Trop. 2012;124(1):42–7.
Herrmann M, et al. Staphylococcal disease in Africa: another neglected ‘tropical’ disease. Future Microbiol. 2013;8(1):17–26.
Alabi AS, et al. Retrospective analysis of antimicrobial resistance and bacterial spectrum of infection in Gabon, Central Africa. BMC Infect Dis. 2013;13:455.
Schaumburg F, et al. Virulence factors and genotypes of Staphylococcus aureus from infection and carriage in Gabon. Clin Microbiol Infect. 2011;17(10):1507–13.
Ehrhardt J, et al. Population structure of Legionella spp. from environmental samples in Gabon. Infect Genet Evol. 2013;2015(33):299–303.
Schaumburg F, et al. Streptococcus pneumoniae colonization in remote African Pygmies. Trans R Soc Trop Med Hyg. 2013;107(2):105–9.
Druml C. Bioethics internationally and in Austria: a sense of solidarity. Wien Klin Wochenschr. 2016;128(7–8):229–33.
Miiro GM, et al. EDCTP regional networks of excellence: initial merits for planned clinical trials in Africa. BMC Public Health. 2013;13:258.